Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROLLING WAVES
NCT00268645Phase 4Completed
- Sponsor
- Sanofi
- Start
- Sep 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoints: Fasting Blood Glucose at 3 months and Glycated Hemoglobin at 3 months. Started Sep 2004; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00268645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268645.